Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Intravenous Human Umbilical Cord-Derived Mesenchymal Stromal Cells Promote Functional Recovery after Experimental Intracerebral Hemorrhage Via Local and Systemic Immunomodulation

Tsuji S., Kuramoto Y., Takeda Y., Doe N., Yamahara K., Yoshimura S.

Animal Study on Chronic Inflammation, Immune Modulation, published in Transl Stroke Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Transl Stroke Res (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41507510
PMCID
PMC12783308
DOI
10.1007/s12975-025-01408-3

Abstract (original English)

Intracerebral hemorrhage (ICH) is associated with high mortality and disability, and current treatments offer limited benefits for functional recovery. Human umbilical cord-derived mesenchymal stromal cell (hUCMSC) have strong proliferative, neuroprotective, and immunomodulatory properties, making them attractive for clinical translation. We evaluated the therapeutic effects of intravenously administered hUCMSCs in a collagenase-induced ICH model using male mice. Mice received low or high doses of hUCMSC once or twice within 72 h after ICH. Repeated high-dose administration significantly improved motor, cognitive, and affective behaviors. Although repeated administration of high-dose hUCMSCs produced the most pronounced behavioral recovery, most subsequent analyses were performed using the single-dose groups. Histological analysis showed reduced neuronal apoptosis and microglial activation, consistent with neuroprotection. In vitro assays demonstrated suppression of inflammatory gene expression and promotion of an anti-inflammatory phenotype in immune cells. Flow cytometry revealed selective reduction of pro-inflammatory macrophages and microglia, increased reparative subsets, and systemic modulation of myeloid dynamics. Our results suggest that intravenous hUCMSC administration at a higher dose confers robust neuroprotection through coordinated local and systemic immunomodulat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MicrogliaMesenchymal Stem CellsUmbilical CordAnimalsMice, Inbred C57BLHumansMiceCerebral HemorrhageDisease Models, AnimalMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research